

MAR 30 2007

Serial No.: 10/549,323

Atty. Docket No. LNK-007

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of treating and/or preventing a cranial/brain trauma and/or cerebral ischemia comprising the step of administering to a subject in need thereof a medicament comprising an active ingredient selected from the group consisting of: frankincense, frankincense extracts, hydrogenation products of frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives, physiologically acceptable salts of said derivative, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a boswellic acid derivative, and a boswellic acid-containing vegetable preparation.
2. (Previously Presented) The method according to claim 1, wherein the cerebral ischemia occurs as a result of apoplexy, cardiac infarction or an operation.
3. (Previously Presented) The method according to claim 1, wherein the active ingredient comprises frankincense or a boswellic acid-containing vegetable extract.
4. (Currently Amended) The method according to claim 1, wherein the ~~active ingredient~~ frankincense extract is selected from the group consisting of a keto-boswellic acid, 3-O-acetyl-11-keto- $\beta$ -boswellic acid, 11-keto- $\beta$ -boswellic acid, a physiologically acceptable salt of a keto-boswellic acid, a derivative of a keto-boswellic acid, a salt of a keto-boswellic acid derivative, and a keto-boswellic acid-containing vegetable extract.

Serial No.: 10/549,323

Atty. Docket No. LNK-007

5. (Currently Amended) The method according to claim 1, wherein the ~~active ingredient~~ frankincense extract comprises a tirucallic acid, another triterpene or a salt or derivative thereof or a vegetable extract containing a tirucallic acid, another triterpene or a salt or derivative thereof.
6. (Currently Amended) The method according to claim 1, wherein the ~~active ingredient~~ frankincense extract comprises an extract from a *Boswellia serrata* resin.
7. (Previously Presented) A method of treating and/or preventing a cranial/brain trauma, cerebral ischemia and/or Alzheimer's disease comprising the step of administering to a subject in need thereof a medicament comprising an active ingredient selected from the group consisting of: hydrogenation products of frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives, physiologically acceptable salts of said derivatives, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a boswellic acid derivative, and a boswellic acid-containing vegetable preparation.
8. (Previously Presented) The method according to claim 7, wherein the medicament is used for preventing and/or treating Alzheimer's disease.
9. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenation product of a boswellic acid-containing vegetable extract.
10. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenated extract from a *Boswellia serrata* resin.

Serial No.: 10/549,323

Atty. Docket No. LNK-007

11. (Previously Presented) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a hydrogenation product of boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative thereof, a salt of a boswellic acid derivative, and a boswellic acid-containing vegetable preparation.
12. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises dihydroboswellic acid.
13. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenation product is selected from the group consisting of  $\beta$ -dihydroboswellic acid acetate,  $\beta$ -dihydroboswellic acid formate,  $\beta$ -dihydroboswellic acid methyl ester, acetyl- $\beta$ -dihydroboswellic acid,  $\alpha$ -dihydroboswellic acid, acetyl- $\alpha$ -dihydroboswellic acid and formyl- $\alpha$ -dihydroboswellic acid.
14. (Previously Presented) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a keto-dihydroboswellic acid, acetyl-11-keto- $\beta$ -dihydroboswellic acid, 11-keto- $\beta$ -dihydroboswellic acid, formyl-11-keto- $\beta$ -dihydroboswellic acid, a physiologically acceptable salt of a keto-dihydroboswellic acid, a derivative of a keto-dihydroboswellic acid, a salt of a keto-dihydroboswellic acid derivative, and a hydrogenated keto-boswellic acid-containing vegetable extract.
15. (Previously Presented) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a hydrogenation product of tirucallic acid, a salt of said hydrogenation product, a derivative of said hydrogenation product or salt thereof, and a hydrogenated tirucallic acid-containing vegetable extract.

**Serial No.: 10/549,323**

**Atty. Docket No. LNK-007**

16. (Previously Presented) The method according to claim 1, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

17. (Previously Presented) The method according to claim 1, wherein the medicament comprises a tablet or solution.

18. (Previously Presented) The method according to claim 7, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

19. (Previously Presented) The method according to claim 7, wherein the medicament comprises a tablet or solution.